Fabre-Kramer Pharmaceuticals, Inc., is a pharmaceutical company which identifies, develops and commercializes psychotropic drugs. The Company’s principals have over 40 years of experience in the clinical development of psychotropic drugs and have conducted pivotal studies of many drugs approved by the FDA in psychiatry. They have conducted studies in depression, anxiety, schizophrenia, bipolar disorder, social phobia and sleep disorders. They also have over 40 years of experience in in-patient and out-patient psychiatry, have intimate knowledge of the treatment of Central Nervous System disorders and have analyzed many potential psychotropic compounds from the standpoint of receptor activity, efficacy, tolerability, side effect/benefit ratio, formulation, ease of administration, cost, and ease of manufacturing. At Fabre-Kramer Pharmaceuticals, our goal is to develop and bring to market advanced new medications to help physicians treat their patients’ unmet medical needs. The Company is in an excellent position to identify and acquire promising psychotropic drugs that, for a variety of reasons, are available from major pharmaceutical companies and other industry and academic sources.